Evidence map›Paper›PMID 40200430›Full record

ArticleAnnals of clinical and translational neurology2025

Clinical Phenotyping of Long COVID Patients Evaluated in a Specialized Neuro-COVID Clinic.

Luana D Yamashita, Neel Desai, Abigail R Manning, Caitlin Pileggi, Sara Manning Peskin, Danielle K Sandsmark, Dennis L Kolson, Matthew K Schindler

Erratum issuedAbstract read
In one paragraph

Article in Annals of clinical and translational neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Cognitive impairment in long-COVID: frequency, trajectories and risk factors in a cohort study from Italy.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026
    Article
  4. Cognition and Long COVID: a Review.Current neurology and neuroscience reports · 2026
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors.

Luana D YamashitaDepartment of Neurology, University of Pennsylvania, Philadelphia, Pennsylvania, USA.ORCID 0009-0008-8402-5040
Neel DesaiDepartment of Biostatistics, Epidemiology, and Informatics, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Abigail R ManningDepartment of Neurology, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Caitlin PileggiDepartment of Neurology, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Sara Manning PeskinDepartment of Neurology, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Danielle K SandsmarkDepartment of Neurology, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Dennis L KolsonDepartment of Neurology, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Matthew K SchindlerDepartment of Neurology, University of Pennsylvania, Philadelphia, Pennsylvania, USA.ORCID 0000-0003-0157-5669

Funding

Protection against early SIV brain injury with adjunctive therapy to cARTR01NS122570 · NINDS · UNIVERSITY OF PENNSYLVANIA · PI Dennis Larry Kolson · 2022 to 2026
$3.9M
NINDS NIH HHS R01 NS122570
6 · The paper itself

Abstract

objectiveTo report Long COVID characteristics and longitudinal courses of patients evaluated between 4/14/21-4/14/22 at the University of Pennsylvania Neurological COVID Clinic (PNCC), including clinical symptoms, neurological examination findings, and neurocognitive screening tests from a standardized PNCC neurological evaluation approach.

methodsThis is a retrospective cross-sectional and longitudinal study in a single-center tertiary care academic center. Participants include 240 patients with documented evidence of a positive SARS-CoV-2 PCR or antibody test who underwent initial evaluation and 182 patients with longitudinal follow-up. Main outcomes evaluated are patient demographics, duration of illness prior to self-reported improvement, and cognitive testing results-including the Montreal Cognitive Assessment (version 8.2) (MoCA) and Oral Trail Making Test-B (OTMT-B).

resultsThe majority (73%) of patients did not require hospitalization for their acute COVID-19 symptoms. Frequent Long COVID complaints included headache (60%), dizziness/vertigo (40%), and disturbance of taste/smell (40%). Almost all (94%) patients reported cognitive symptoms, and over 30% of patients had abnormal scores on cognitive testing. Severe infection, fewer years of education level, and non-White race were found to be statistically associated with an increased likelihood of having abnormal scores on cognitive testing. Neuroimaging and clinical laboratory testing were largely not informative for patient care. Sixty-two percent of patients with follow-up visits self-reported improvement in their primary neurological complaint within 1 year of evaluation.

interpretationPerformance on standardized cognitive screening tests may not be consistent with frequently reported cognitive complaints in Long COVID patients. The most common clinical trajectory was self-reported improvement in the primary neurological symptom.

Indexed as

Cognitive DysfunctionCOVID-19AdultAgedCross-Sectional StudiesFemaleHumansLongitudinal StudiesMaleMiddle AgedNeuropsychological TestsPhenotypePost-Acute COVID-19 SyndromeRetrospective StudiesSARS-CoV-2brain fogcognitivelong COVIDMoCApost‐COVID

Identifiers

PMID40200430
PMCPMC12172097

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.